• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苯溴马隆泡腾颗粒与别嘌醇降尿酸作用的比较研究(作者译)

[The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].

作者信息

Mertz D P

出版信息

MMW Munch Med Wochenschr. 1978 Oct 20;120(42):1387-90.

PMID:101792
Abstract

The daily administration of 25 mg effervescent granules is about equipotent with a daily dose of 200 mg allopurinol, giving due attention to the caution necessary for uricosuric therapy. The daily administration of 50 mg benzbromarone effervescent granules has a slight but significantly greater uric acid-lowering effect than treatment with 300 mg allopurinol per day. The tolerance of benzbromarone in the active form named was good in all cases. Side effects were not observed. Since benzbromarone as effervescent granules is taken with plenty of fluid this takes care of an increased fluid intake and introduces a motivation for doing so.

摘要

每日服用25毫克泡腾颗粒的效果与每日服用200毫克别嘌醇大致相当,同时要充分注意促尿酸排泄疗法所需的注意事项。每日服用50毫克苯溴马隆泡腾颗粒的降尿酸效果比每日服用300毫克别嘌醇略有增强,但差异显著。在所有病例中,上述活性形式的苯溴马隆耐受性良好,未观察到副作用。由于苯溴马隆泡腾颗粒需与大量液体一起服用,这有助于增加液体摄入量,并且提供了这样做的动力。

相似文献

1
[The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].苯溴马隆泡腾颗粒与别嘌醇降尿酸作用的比较研究(作者译)
MMW Munch Med Wochenschr. 1978 Oct 20;120(42):1387-90.
2
[Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].[低剂量降尿酸药物对高尿酸血症合并高甘油三酯血症患者的随机分组研究效应]
Fortschr Med. 1979 Jul 19;97(27):1212-4.
3
[Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].苯溴马隆(立加利仙)通过增加尿酸排泄降低尿酸的作用
Fortschr Med. 1979 May 3;97(17):835-6.
4
[Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].[别嘌醇与苯溴马隆单一及联合治疗。肾脏对致石物质和胶体保护物质的排泄(作者译)]
Med Klin. 1977 Apr 15;72(15):664-8.
5
[Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
Dtsch Med Wochenschr. 1976 Aug 27;101(35):1288-92. doi: 10.1055/s-0028-1104258.
6
Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid.苯溴马隆治疗高尿酸血症;与别嘌醇和丙磺舒的比较。
J Int Med Res. 1981;9(6):511-5. doi: 10.1177/030006058100900615.
7
Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.苯溴马隆与别嘌醇相比在降低高尿酸血症患者血清尿酸水平方面的疗效。
J Med Assoc Thai. 2002 Jun;85 Suppl 1:S40-7.
8
[Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].别嘌醇与苯溴马隆联合治疗高尿酸血症(作者译)
Dtsch Med Wochenschr. 1976 Oct 22;101(43):1568-70. doi: 10.1055/s-0028-1104304.
9
[Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
Arzneimittelforschung. 1983;33(12):1687-91.
10
[Effectiveness and tolerance of long-term uricosuric treatment].[长期尿酸排泄促进治疗的有效性和耐受性]
Z Gesamte Inn Med. 1990 Dec 1;45(23):719-20.

引用本文的文献

1
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?苯溴马隆治疗痛风的获益-风险评估。其退市符合患者的最大利益吗?
Drug Saf. 2008;31(8):643-65. doi: 10.2165/00002018-200831080-00002.